The NCI-60 cancer cell line panel is a group of 60 human cancer cell lines used by the National Cancer Institute (NCI) for the screening of compounds to detect potential anticancer activity.[1]
The screening procedure is called the NCI-60 Human Tumor Cell Lines Screen, and it is one of the Discovery & Development Services of NCI's Developmental Therapeutics Program (DTP).[2][3][4] The screening rates for each cell line the cytostatic and cytotoxic impact of tested substances.[2]
Due to the diversity of the cell lines, it is possible to compare tested compounds by their effect patterns, high correlation potentially corresponding to similar effect mechanisms.[2] An automated comparison against a database of more than 88,000 pure compounds and more than 34,000 crude extracts (as of 6 January 2017[update]) is provided by the COMPARE tool, which shows a list of substances ranked by the Pearson correlation coefficients for a given test substance.[5]
The same panel is used in the Molecular Target Program for the characterization of molecular targets. Measurements include protein levels, RNA measurements, mutation status and enzyme activity levels.[6]
The panel holds cell lines representing leukemia, melanoma, non-small-cell lung carcinoma, and cancers of the brain, ovary, breast, colon, kidney, and prostate.[1][2]
13 additional cell lines are evaluated for use in the screening program, among them two lines deriving from so far not represented small-cell lung carcinoma.[1]
All cell lines but one (as of 6 January 2017[update]) are available to other laboratories, including the additional cell lines.[1]
Starting around the turn of the millennium, several cell lines were found to be misidentified or misclassified at the time of investigation or earlier:[7][8][9]
MDA-MB-435, originally classified as breast cancer cell line, was identified as being a melanoma cell line.[7] When investigated further, current MDA-MB-435 appeared to be derived from the same individual as cell line M14.[7] An examination of clones made clear that the mixup with M14 happened very early in the history of MDA-MB-435, before establishment in the Developmental Therapeutics Program.[7]
NCI/ADR-RES, originally classified as breast cancer cell line, was identified as being an ovarian tumor cell line.[8] NCI/ADR-RES appears to have been derived at some point in time from cell line OVCAR-8.[8] Originally the cell line was named MCF-7/ADR-RES; it was renamed together with the change in classification.[8]
Two brain cancer cell lines, SNB-19 and U251, were discovered to come from the same person.[9] This makes a mixup likely.
A 61st cell line, MDA-N, has been confirmed to being derived from the misclassified MDA-MB-435 cell line.[7] So it is also misclassified, really being a melanoma cell line, but as of 6 January 2018[update] the official website still lists it as breast cancer cell line.[1] This cell line is not available as of 6 January 2018[update].[1]
The International Cell Line Authentication Committee maintains a list of contaminated cell lines.[10] It includes the cell lines reported above, although usually with reporting dates and articles considerably later than the first dates and articles rising specific concern regarding the respective cell line.[10][7][8][9]
As of 2014[update] Hundreds of research studies still use MDA-MB-435 as model of breast cancer, even after it was officially declared to be a melanoma cell line in 2007, and even in highest-rated international peer-reviewed journals.[11] Similar is true for other misidentified cell lines.[11]
Cell line | Tumor classification | (Potentially) misidentified | Original classification | Unavailable | Doubling Time (Hours) | Inoculation Density | Cellosaurus identifier and link | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CCRF-CEM | Leukemia | 26.7 | 40000 | CCRF-CEM (RRID:CVCL_0207) | ||||||||||||
HL-60(TB) | Leukemia | 28.6 | 40000 | HL-60(TB) (RRID:CVCL_A794) | ||||||||||||
K-562 | Leukemia | 19.6 | 5000 | K-562 (RRID:CVCL_0004) | ||||||||||||
MOLT-4 | Leukemia | 27.9 | 30000 | MOLT-4 (RRID:CVCL_0013) | ||||||||||||
RPMI-8226 | Leukemia | 33.5 | 20000 | RPMI-8226 (RRID:CVCL_0014) | ||||||||||||
SR-786 | Leukemia | 28.7 | 20000 | SR (RRID:CVCL_1711) | ||||||||||||
A549 | Non-Small Cell Lung | 22.9 | 7500 | A-549 (RRID:CVCL_0023) | ||||||||||||
EKVX | Non-Small Cell Lung | 43.6 | 20000 | EKVX (RRID:CVCL_1195) | ||||||||||||
HOP-62 | Non-Small Cell Lung | 39 | 10000 | HOP-62 (RRID:CVCL_1285) | ||||||||||||
HOP-92 | Non-Small Cell Lung | 79.5 | 20000 | HOP-92 (RRID:CVCL_1286) | ||||||||||||
NCI-H226 | Non-Small Cell Lung | 61 | 20000 | NCI-H226 (RRID:CVCL_1544) | ||||||||||||
NCI-H23 | Non-Small Cell Lung | 33.4 | 20000 | NCI-H23 (RRID:CVCL_1547) | ||||||||||||
NCI-H322M | Non-Small Cell Lung | 35.3 | 20000 | NCI-H322M (RRID:CVCL_1557) | ||||||||||||
NCI-H460 | Non-Small Cell Lung | 17.8 | 7500 | NCI-H460 (RRID:CVCL_0459) | ||||||||||||
NCI-H522 | Non-Small Cell Lung | 38.2 | 20000 | NCI-H522 (RRID:CVCL_1567) | ||||||||||||
COLO 205 | Colon | 23.8 | 15000 | COLO 205 (RRID:CVCL_0218) | ||||||||||||
HCC-2998 | Colon | 31.5 | 15000 | HCC2998 (RRID:CVCL_1266) | ||||||||||||
HCT116 | Colon | 17.4 | 5000 | HCT 116 (RRID:CVCL_0291) | ||||||||||||
HCT-15 | Colon | 20.6 | 10000 | HCT 15 (RRID:CVCL_0292) | ||||||||||||
HT-29 | Colon | 19.5 | 5000 | HT-29 (RRID:CVCL_0320) | ||||||||||||
KM12 | Colon | 23.7 | 15000 | KM12 (RRID:CVCL_1331) | ||||||||||||
SW-620 | Colon | 20.4 | 10000 | SW620 (RRID:CVCL_0547) | ||||||||||||
SF-268 | CNS | 33.1 | 15000 | SF268 (RRID:CVCL_1689) | ||||||||||||
SF-295 | CNS | 29.5 | 10000 | SF295 (RRID:CVCL_1690) | ||||||||||||
SF-539 | CNS | 35.4 | 15000 | SF539 (RRID:CVCL_1691) | ||||||||||||
SNB-19 | CNS | yes | CNS | 34.6 | 15000 | SNB-19 (RRID:CVCL_0535) | ||||||||||
SNB-75 | CNS | 62.8 | 20000 | SNB-75 (RRID:CVCL_1706) | ||||||||||||
U251 | CNS | yes | CNS | 23.8 | 7500 | U-251MG (RRID:CVCL_0021) | ||||||||||
LOX IMVI | Melanoma | 20.5 | 7500 | LOX-IMVI (RRID:CVCL_1381) | ||||||||||||
MALME-3M | Melanoma | 46.2 | 20000 | Malme-3M (RRID:CVCL_1438) | ||||||||||||
M14 | Melanoma | 26.3 | 15000 | M14 (RRID:CVCL_1395) | ||||||||||||
MDA-MB-435 | Melanoma | yes | Breast | 25.8 | 15000 | MDA-MB-435 (RRID:CVCL_0417) | ||||||||||
SK-MEL-2 | Melanoma | 45.5 | 20000 | SK-MEL-2 (RRID:CVCL_0069) | ||||||||||||
SK-MEL-28 | Melanoma | 35.1 | 10000 | SK-MEL-28 (RRID:CVCL_0526) | ||||||||||||
SK-MEL-5 | Melanoma | 25.2 | 10000 | SK-MEL-5 (RRID:CVCL_0527) | ||||||||||||
UACC-257 | Melanoma | 38.5 | 20000 | UACC-257 (RRID:CVCL_1779) | ||||||||||||
UACC-62 | Melanoma | 31.3 | 10000 | UACC-62 (RRID:CVCL_1780) | ||||||||||||
IGROV-1 | Ovarian | 31 | 10000 | IGROV-1 (RRID:CVCL_1304) | ||||||||||||
OVCAR-3 | Ovarian | 34.7 | 10000 | OVCAR-3 (RRID:CVCL_0465) | ||||||||||||
OVCAR-4 | Ovarian | 41.4 | 15000 | OVCAR-4 (RRID:CVCL_1627) | ||||||||||||
OVCAR-5 | Ovarian | 48.8 | 20000 | OVCAR-5 (RRID:CVCL_1628) | ||||||||||||
OVCAR-8 | Ovarian | 26.1 | 10000 | OVCAR-8 (RRID:CVCL_1629) | ||||||||||||
NCI/ADR-RES (originally MCF-7/ADR-RES) | Ovarian | yes | Breast | 34 | 15000 | NCI-ADR-RES (RRID:CVCL_1452) | ||||||||||
SK-OV-3 | Ovarian | 48.7 | 20000 | SK-OV-3 (RRID:CVCL_0532) | ||||||||||||
786-O | Renal | 22.4 | 10000 | 786-O (RRID:CVCL_1051) | ||||||||||||
A498 | Renal | 66.8 | 25000 | A-498 (RRID:CVCL_1056) | ||||||||||||
ACHN | Renal | 27.5 | 10000 | ACHN (RRID:CVCL_1067) | ||||||||||||
CAKI-1 | Renal | 39 | 10000 | Caki-1 (RRID:CVCL_0234) | ||||||||||||
RXF 393 | Renal | 62.9 | 15000 | RXF 393L (RRID:CVCL_1673) | ||||||||||||
SN12C | Renal | 29.5 | 15000 | SN12C (RRID:CVCL_1705) | ||||||||||||
TK-10 | Renal | 51.3 | 15000 | TK-10 (RRID:CVCL_1773) | ||||||||||||
UO-31 | Renal | 41.7 | 15000 | UO-31 (RRID:CVCL_1911) | ||||||||||||
PC-3 | Prostate | 27.1 | 7500 | PC-3 (RRID:CVCL_0035) | ||||||||||||
DU-145 | Prostate | 32.3 | 10000 | DU145 (RRID:CVCL_0105) | ||||||||||||
MCF7 | Breast | 25.4 | 10000 | MCF-7 (RRID:CVCL_0031) | ||||||||||||
MDA-MB-231 | Breast | 41.9 | 20000 | MDA-MB-231 (RRID:CVCL_0062) | ||||||||||||
MDA-MB-468 | Breast | 62 | 2000 | MDA-MB-468 (RRID:CVCL_0419) | HS 578T | Breast | 53.8 | 20000 | Hs 578T (RRID:CVCL_0332) | |||||||
MDA-N | Melanoma | yes | Breast | unavailable | 22.5 | 15000 | MDA-N (RRID:CVCL_1910) | |||||||||
BT-549 | Breast | 53.9 | 20000 | BT-549 (RRID:CVCL_1092) | ||||||||||||
T-47D | Breast | 45.5 | 20000 | T-47D (RRID:CVCL_0553) |
Cell line | Tumor classification | Species | Inoculation Density | Cellosaurus identifier and link |
---|---|---|---|---|
LXFL 529 | Non-Small Cell Lung | human | 10000 | LXFL 529L (RRID:CVCL_D085) |
DMS 114 | Small Cell Lung | human | 20000 | DMS 114 (RRID:CVCL_1174) |
SHP-77 | Small Cell Lung | human | 40000 | SHP-77 (RRID:CVCL_1693) |
DLD-1 | Colon | human | 50000 | DLD-1 (RRID:CVCL_0248) |
KM20L2 | Colon | human | 10000 | KM20L2 (RRID:CVCL_D889) |
SNB-78 | CNS | human | 20000 | SNB-78 (RRID:CVCL_B321) |
XF 498 | CNS | human | 20000 | XF 498 (RRID:CVCL_8928) |
RPMI-7951 | Melanoma | human | 20000 | RPMI-7951 (RRID:CVCL_1666) |
M19-MEL | Melanoma | human | 10000 | M19-MEL (RRID:CVCL_B415) |
RXF-631 | Renal | human | 10000 | RXF 631L (RRID:CVCL_A780) |
SN12K1 | Renal | human | 10000 | SN12K1 (RRID:CVCL_D106) |
P388 | Leukemia | mouse | 50000 | P388 (RRID:CVCL_7222) |
P388/ADR | Leukemia | mouse | 50000 | P388/ADR (RRID:CVCL_IZ75) |